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Abstract
Introduction: Little is known about the pathophysiology of hyperemesis gravidarum 
(HG). Proposed underlying causes are multifactorial and thyroid function is hypoth-
esized to be causally involved. In this study, we aimed to assess the utility of thyroid- 
stimulating hormone (TSH) and free thyroxine (FT4) as a marker and predictor for the 
severity and clinical course of HG.
Material and methods: We conducted a prospective cohort study including women 
admitted for HG between 5 and 20 weeks of gestation in 19 hospitals in the 
Netherlands. Women with a medical history of thyroid disease were excluded. TSH 
and FT4 were measured at study entry. To adjust for gestational age, we calculated 
TSH multiples of the median (MoM). We assessed HG severity at study entry as se-
verity of nausea and vomiting (by the Pregnancy Unique Quantification of Emesis and 
nausea score), weight change compared with prepregnancy weight, and quality of life. 
We assessed the clinical course of HG as severity of nausea and vomiting and quality 
of life 1 week after inclusion, duration of hospital admissions, and readmissions. We 
performed multivariable regression analysis with absolute TSH, TSH MoMs, and FT4.
Results: Between 2013 and 2016, 215 women participated in the cohort. TSH, TSH 
MoM, and FT4 were available for, respectively, 150, 126, and 106 of these women. 
Multivariable linear regression analysis showed that lower TSH MoM was signifi-
cantly associated with increased weight loss or lower weight gain at study entry 
(ΔKg; β = 2.00, 95% CI 0.47- 3.53), whereas absolute TSH and FT4 were not. Lower 
TSH, not lower TSH MoM or FT4, was significantly associated with lower nausea and 
vomiting scores 1 week after inclusion (β = 1.74, 95% CI 0.36- 3.11). TSH and FT4 
showed no association with any of the other markers of the severity or clinical course 
of HG. Twenty- one out of 215 (9.8%) women had gestational transient thyrotoxicosis. 
Women with gestational transient thyrotoxicosis had a lower quality of life 1 week 
after inclusion than women with no gestational transient thyrotoxicosis (p = 0.03).
Conclusions: Our findings show an inconsistent role for TSH, TSH MoM, or FT4 at 
time of admission and provide little guidance on the severity and clinical course of HG.
K E Y W O R D S
disease severity marker, free thyroxine, hyperemesis gravidarum, nausea and vomiting in 
pregnancy, thyroid function, thyroid- stimulating hormone
1  |  INTRODUC TION
Hyperemesis gravidarum (HG) is a severe form of nausea and vomit-
ing in pregnancy (NVP) affecting 0.3%- 3.6% of pregnancies.1,2 HG is 
the most common reason for hospital admission in early pregnancy, 
but evidence- based effective treatment options are currently lim-
ited.3,4 Because of the major impact of HG on maternal well- being 
and quality of life, a marker that could help to identify the severity 
and clinical course of HG would be of value for assessing a patient's 
prognosis and individualizing patient care.5- 8
Little is known about the pathophysiology of HG. Proposed un-
derlying causes are multifactorial and related to maternal endocrine 
and placental function as well as to gastrointestinal conditions, al-
though recently genetic causes, including involvement of the growth 
differentiation factor- 15 gene (GDF15), a cachexia gene, and its re-
ceptor have been implicated.9,10
Key message
Thyroid measurement in women admitted for hyperemesis 
gravidarum provides little guidance on predicting disease 
severity and course.
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Increased human chorionic gonadotropin (hCG) has been hy-
pothesized to be causally involved in NVP and HG— hCG rises in the 
first trimester, which coincides with the peak in occurrence of NVP 
and HG.11 However, the putative association of increased hCG with 
NVP symptoms was not confirmed upon systematic review, which 
found an association in only half of the included studies.12 An expla-
nation for the apparent discrepancy in findings could lie in the fact 
that hCG and thyroid- stimulating hormone (TSH) have biosimilar 
effects on the TSH receptor, which can result in hCG- induced thy-
roid stimulation, leading to a clinically relevant rise in free thyroxine 
(FT4) and subsequent suppression of TSH levels, a condition known 
as gestational transient thyrotoxicosis (GTT).13 Hyperthyroidism can 
produce nausea, vomiting, and weight loss. Therefore, FT4 and TSH 
might be important factors in the etiology of HG.14 A systematic 
review by Niemeijer et al12 found few studies assessing the effect 
of TSH on the severity and clinical course of HG. We updated this 
systematic review12 in order to put our findings in context, as shown 
in the Supporting Information (Appendix S1 and Table S1). Available 
evidence concerning possible associations between TSH and FT4 
and measures of HG severity and clinical course shows conflicting 
results. None of the studies took gestational fluctuations of TSH 
into account. Niemeijer et al12 called for better investigation of the 
use of TSH adjusted for pregnancy duration in future studies and 
currently no adjusted reference interval is available for gestational 
fluctuations of TSH.
In the present study, we aimed to assess the association be-
tween absolute TSH (without adjustments for gestational fluctua-
tions), TSH multiple of the median (MoM), and FT4 and the severity 
and clinical course of HG to evaluate whether it is useful to measure 
thyroid function in order to predict the severity and clinical course 
of HG.
2  |  MATERIAL AND METHODS
Our study used data from the Maternal and Offspring outcomes 
after Treatment of HyperEmesis by Refeeding (MOTHER) trial and 
associated cohort and is a prospective observational cohort study 
carried out between 2013 and 2016 that included women admit-
ted for HG to 19 hospitals in the Netherlands.15 The MOTHER trial, 
a multicenter open- label randomized controlled trial (RCT), aimed 
to evaluate the effect of early enteral tube feeding in addition to 
standard care for HG patients requiring hospital inpatient care, in-
cluding intravenous fluid and anti- emetic medication. Women who 
were eligible for the RCT but who declined participation were asked 
to participate in the cohort. As early enteral tube feeding had no ef-
fect on perinatal and maternal outcomes, we deemed it appropriate 
to combine data of the RCT and cohort into one study population for 
the present study.15 Participants of both trial and cohort provided 
informed consent.
We included women of 18 years and older who had been ad-
mitted to the hospital for HG between 5 and 20 weeks of gesta-
tion. Women were diagnosed with HG if they had severe nausea 
and vomiting necessitating admission. More detailed description of 
study methodology has been previously published.15
2.1  |  Thyroid- stimulating hormone and 
free thyroxine
According to local protocol, maternal blood was taken during rou-
tine laboratory testing on the first day of admission and analyzed; it 
was also stored frozen in the biobank, as reported in the previously 
published MOTHER protocol.16 If TSH was included in local routine 
workup for HG, TSH was assessed in local laboratory at baseline. In 
August 2019, available frozen stored maternal samples from baseline 
were used to assess FT4 in one central laboratory.
We assessed TSH unadjusted for gestational fluctuations (abso-
lute TSH), but we also calculated TSH MoMs in order to account 
for physiological fluctuation of TSH during pregnancy. To do so, we 
used data from the CATS study from Bestwick et al,17 the largest 
available study in Europe, which assessed TSH medians in healthy 
pregnant women between 7 and 15 weeks of gestation. We calcu-
lated MoMs by dividing the participants’ observed absolute TSH 
concentration by the expected TSH median for corresponding ges-
tational age, as published by Bestwick et al.17 GTT was defined as 
FT4 above 22.0 pmol/L according to the central laboratory's refer-
ence interval.18
2.2  |  Data collection
Trained research staff completed a Case Report Form (CRF) to ex-
tract and report information from medical and obstetric antenatal 
files including age, parity, gestational age, weight, and comorbidity 
at study entry. Prepregnancy weight, ethnicity, and education level 
were self- reported at baseline, and if not reported, extracted from 
medical file, if available.
Severity of HG was measured at baseline by evaluating weight 
change, symptom severity, and quality of life. Weight change was 
defined as weight at baseline minus prepregnancy weight. Symptom 
severity and quality of life were measured by three self- reported 
validated questionnaires, filled out on the first day of inclusion. The 
Pregnancy Unique Quantification of Emesis and nausea (PUQE- 24) 
measures the severity of nausea and vomiting: a higher PUQE- 24 
score (PUQE- 24 ≥13) indicates severe vomiting.19 The Hyperemesis 
Impact of Symptoms (HIS) questionnaire determines the impact 
of nausea and vomiting.20 The Nausea and Vomiting in Pregnancy 
Quality of Life questionnaire (NVPQoL) measures the impact of nau-
sea and vomiting specifically on quality of life.21 A higher NVPQoL 
or HIS score indicates a lower quality of life or higher impact on ma-
ternal well- being.
The clinical course of HG was measured as symptom severity and 
quality of life 1 week after inclusion, duration of hospital admissions, 
and readmissions. We measured symptom severity by PUQE- 24 
score 1 week after inclusion and quality of life by NVPQoL and HIS 
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score 1 week after inclusion. Data on duration of hospital admis-
sions and readmissions were collected from medical files. Duration 
of hospital admissions was measured in days; the day of admission 
and discharge both counted as 1 day.
2.3  |  Statistical analyses
Normally distributed continuous variables are presented as means 
with standard deviations and skewed distributions as medians with 
interquartile ranges. Dichotomous and categorical variables are pre-
sented as frequencies with percentages.
We performed univariable and multivariable linear regression 
analyses to assess the association between absolute TSH, TSH MoM, 
and FT4 and continuous outcome variables. NVPQoL one week after 
inclusion and total days of hospital admission were not normally dis-
tributed and were logarithmically transformed to achieve normality. 
These logarithmically transformed variables were back- transformed 
and reported in proportionate differences and 95% CIs (expressed 
as percentages); normally distributed variables were reported in dif-
ferences (β) and 95% CI. Dichotomous outcome variables were ana-
lyzed using univariable and multivariable logistic regression analyses 
and are reported as odds ratios with 95% CI. In the first model, we 
performed a univariable regression analysis. In the second model, we 
performed a multivariable regression analysis adjusted for age, pre-
pregnancy BMI, ethnicity, and maternal education. Weight change 
was added as a confounder in the multivariable analysis for clinical 
course of HG based on available literature.22
A sensitivity analysis was used for assessing whether baseline 
characteristics and measures of the severity and clinical course of 
HG differed between included and excluded participants in our 
study. We also assessed whether baseline characteristics and mea-
sures of the severity and clinical course of HG differed between 
women with and without GTT, using chi- squared test, Fisher's exact 
test, Mann- Whitney U test, and independent Student's t test. Values 
of p that were <0.05 were considered statistically significant. SPSS 
Statistics 25.0 for Windows (IBM Corp.) was used for all analyses.
2.4  |  Ethical approval
The MOTHER trial and cohort were registered at www.trial regis ter.
nl (NTR4197) and have been approved by the research ethics com-
mittee of the Academic Medical Center (NL41011.018.12) on 3 April 
2013.
3  |  RESULTS
In total, 215 women were included in the combined cohort: 115 
women in the RCT and another 100 women in the associated obser-
vational cohort. Nine women with a medical history of hypo- or hy-
perthyroidism or with a clinical hypothyroidism (TSH ≥4.0 mE/L) at 
time of inclusion were excluded from the analysis (Figure 1). TSH at 
time of inclusion was measured in 150 women. We were able to calcu-
late TSH MoMs for 126 women, based on TSH medians available from 
Bestwick et al,17 and we were able to measure FT4 in 106 women, 
based on the number of frozen stored blood samples available.
Baseline characteristics and measurements of the clinical course 
of HG and disease severity of participants are shown in Table 1. First 
admission at inclusion significantly differed between women with 
(92.7%) and without (80.0%) absolute TSH levels available (p = 0.01) 
(Table S2). Gestational age (p < 0.01) and first admission (p = 0.03) 
at inclusion significantly differed between women with and without 
TSH MoM available, but measurements of the severity and clinical 
course of HG did not (Table S3). We did not find any significant dif-
ferences in baseline characteristics and outcome variables between 
women with and without FT4 available (Table S4).
Lower TSH MoM was significantly associated with increased 
weight loss at baseline compared with prepregnancy weight (kg; 
β = 2.00, 95% CI 0.47- 3.53, p = 0.01), whereas absolute TSH and 
FT4 were not (Tables 2 and 3). Neither TSH, nor TSH MoM, nor FT4 
were significantly associated with other markers of HG severity at 
baseline including the PUQE- 24, HIS, and NVPQoL scores.
Regarding the association between TSH and FT4 and the clinical 
course of HG, we found that lower absolute TSH was significantly 
associated with lower nausea and vomiting scores 1 week after in-
clusion in multivariable regression analysis (β = 1.74, 95% CI 0.36- 
3.11, p = 0.01) (Table 2a). Lower TSH MoM was only significantly 
associated with lower nausea and vomiting scores 1 week after 
inclusion in univariable regression analysis (β = 1.41, 95% CI 0.11- 
2.72, p = 0.03) (Table 2b). FT4 was not associated with the severity of 
nausea and vomiting 1 week after inclusion (Table 3). No significant 
association was found between TSH, TSH MoM, or FT4 and quality 
of life 1 week after inclusion, duration of hospital admissions, and 
readmissions.
Comparing women with and without GTT at baseline, we found 
that women with GTT (n = 21) had a higher HIS score 1 week after 
inclusion then women with no GTT (p = 0.03) as shown in Table 4. No 
significant differences in baseline characteristics or other outcome 
variables were found between women with and without GTT.
4  |  DISCUSSION
We found that, in line with expectations, women who had lower 
TSH MoM, had more weight loss upon hospitalization with HG. 
Furthermore, 10% of women hospitalized with HG had concurrent 
GTT, associated with higher HIS scores 1 week after inclusion. In con-
trast to the literature, and not in line with expectations, lower TSH 
was also associated with markedly lower nausea and vomiting scores 
1 week after baseline. Thyroid function showed no association with 
any of the other outcome measures of disease severity or course of 
HG. The fact that our findings present an inconsistent role for thyroid 
function in HG does not support the use of thyroid measurements as 
marker or predictor for HG disease severity and clinical course.
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F I G U R E  1  Flowchart of study population inclusions and exclusions 
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In our search to identify markers of disease severity among 
newly diagnosed HG patients, our study found that lower TSH MoM 
was associated with increased weight loss in women admitted for 
HG, but FT4 was not. This is in contrast with existing literature that 
hypothesized that hyperthyroidism, and hence increased FT4, leads 
to weight loss.14,23,24 However, an alternative explanation may be 
more likely: in healthy pregnant women without HG, lower mater-
nal weight gain is also associated with lower TSH, when taking into 
account the graded decrease in TSH over the first trimester, sug-
gesting that low TSH and not FT4 may simply be a marker of low 
TA B L E  1  Baseline characteristics 
for women admitted for hyperemesis 
gravidarum included in this cohort
N = 215 % Missing
Demographics
Age (years) 28.83 ± 4.83 0.0%
Prepregnancy weight (kg) 71.11 ± 15.02 2.3%
Prepregnancy BMI (kg/m2) 25.12 ± 4.89 3.7%
Ethnic origin
Western 123 (57.2%) 18.1%
Non- western 53 (24.7%)
Education level
Primary or secondary 86 (40.0%) 34.0%
Higher 56 (26.0%)
Mental health disorder in medical historya  41 (19.1%) 0.0%
HG in previous pregnancyb  68 (45.0%) 15.2%
HG in previous pregnancy requiring hospital admissionb  37 (24.5%) 10.3%
Thyroid- stimulating hormone 0.78 ± 0.61 30.2%
Free thyroxine 19.26 ± 4.76 50.7%
Pregnancy characteristics
Primigravida 64 (29.8%) 0.0%
Twin pregnancy 5 (2.3%) 0.0%
Gestational age at onset of symptoms of HG (weeks) 6.00 (5.25- 7.00) 23.3%
Gestational age at inclusion 9.00 (7.00- 11.00) 0.0%
First admission at study entry 191 (88.8%) 0.0%
Outcomes
HG severity at baseline
Weight change (kg) −2.92 ± 4.07 2.8%
PUQE−24 10.01 ± 3.30 37.2%
NVPQoL 173.44 ± 23.43 34.9%
HIS 27.77 ± 3.86 34.4%
Clinical course of HG
PUQE−24 1 week after inclusion 9.00 (6.00- 11.00) 45.6%
NVPQoL 1 week after inclusion 76.00 (61.00- 100.50) 49.3%
HIS 1 week after inclusion 25.71 ± 3.82 49.3%
Duration of first admission (days) 4.00 (3.00- 5.00) 0.0%
Total days of hospital admission for HG 5.00 (3.00- 8.00) 0.0%
Readmitted 71 (33.0%) 0.0%
Readmitted two or more times 29 (13.5%) 0.0%
Data represented with mean ± standard deviation and median (interquartile range), unless stated 
otherwise; frequency (%).
Abbreviations: BMI, body mass index; HG, hyperemesis gravidarum; PUQE- 24, 24- hour Pregnancy 
Unique Quantification of Emesis and nausea score. Weight change is weight at baseline minus 
prepregnancy weight and can be <0 if women lost weight and can be >0 if women gained weight. 
HIS, Hyperemesis Impact of Symptoms; NVPQoL, Nausea and Vomiting in Pregnancy Quality of Life. 
A higher PUQE- 24, HIS- or NVPQoL- score indicates more severe symptoms or lower quality of life.
aMental health disorder consists of an eating disorder, anxiety disorder, or a depressive disorder. 
bPercentage shown is frequency divided by number of multigravidas. 
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maternal weight gain, and not a cause. Literature showing decreas-
ing TSH levels in obese non- pregnant patients who lost weight after 
caloric restriction or bariatric surgery supports this theory.25- 27 Our 
study did not track TSH and maternal weight over time before HG 
symptoms developed, so we were unable to test this hypothesis.
We also sought to identify whether TSH or FT4 could be helpful 
in identifying women with HG who were to have a more severe or 
prolonged course of illness. In contrast to what had been suggested 
by the literature, our study found that only a lower TSH at baseline 
was associated with lower nausea and vomiting scores (PUQE- 24 
<13) 1 week after inclusion, whereas FT4 was not. An explanation 
could be that an increased energy intake during this period led to an 
increase and normalization of TSH levels, because there is evidence 
that there is a direct relation between TSH and energy intake.28
TA B L E  2  Multivariable linear and logistic regression to assess the association between absolute TSH (a) and TSH MoM (b) and measures 
of the severity and clinical course of HG
Model 1 Model 2
β 95% CI p β 95% CI p
(a) Absolute TSH
HG severity at baseline
Weight change 0.82 −0.20 to 1.84 0.12 0.94 −0.43 to 2.32 0.18
PUQE- 24 −0.15 −1.21 to 0.91 0.78 −0.43 −1.60 to 0.74 0.47
NVPQoL −5.71 −12.19 to 0.78 0.08 −5.63 −12.90 to 1.65 0.13
HIS 0.49 −0.67 to 1.65 0.40 1.03 −0.35 to 2.41 0.14
Clinical course of HG
PUQE- 24 1 week after inclusion 1.02 −0.03 to 2.06 0.06 1.74 0.36- 3.11 0.01
NVPQoL 1 week after inclusion ∫ 8.65 −5.92 to 25.36 0.26 1.11 −15.55 to 21.17 0.90
HIS 1 week after inclusion 0.09 −1.30 to 1.48 0.90 1.04 −0.69 to 2.76 0.23
Total days of hospital admission for HG ∫ 2.43 −14.02 to 21.90 0.79 −0.20 −22.89 to 29.30 0.99
OR 95% CI p OR 95% CI p
Readmitted yes or no 1.55 0.90- 2.68 0.11 1.87 0.85- 4.13 0.12
Readmitted two or more times 1.14 0.55- 2.38 0.72 0.76 0.27- 2.09 0.59
β 95% CI p β 95% CI p
(b) TSH MoM
HG severity at baseline
Weight change 1.54 0.35- 2.73 0.01 2.00 0.47- 3.53 0.01
PUQE- 24 0.24 −0.96 to 1.43 0.70 0.13 −1.26 to 1.52 0.85
NVPQoL −2.71 −9.80 to 4.38 0.45 −4.28 −12.31 to 3.76 0.29
HIS 0.75 −0.64 to 2.14 0.29 1.33 −0.39 to 3.05 0.13
Clinical course of HG
PUQE- 24 1 week after inclusion 1.41 0.11- 2.72 0.03 1.74 −0.02 to 3.50 0.05
NVPQoL 1 week after inclusion ∫ 4.50 −11.22 to 23.00 0.59 −2.27 −20.71 to 20.32 0.82
HIS 1 week after inclusion −0.07 −1.68 to 1.54 0.93 0.90 −1.08 to 2.88 0.37
Total days of hospital admission for HG ∫ −0.50 −19.99 to 23.74 0.96 −4.97 −33.30 to 35.53 0.77
OR 95% CI p OR 95% CI p
Readmitted yes or no 1.27 0.64- 2.50 0.50 1.72 0.62- 4.80 0.30
Readmitted two or more times 1.49 0.62- 3.59 0.38 1.23 0.36- 4.23 0.75
A P value <0.05 was considered significant, represented with the corresponding 95% CI. β is the unstandardized regression coefficient. OR is the 
odds ratio. ∫ is log transformed, back transformed and expressed in % of difference. Weight change is weight at baseline minus prepregnancy weight 
and can be <0 if women lost weight and can be >0 if women gained weight.
Abbreviations: BMI, body mass index; HG, hyperemesis gravidarum; HIS, hyperemesis impact score; NVPQoL, Nausea and Vomiting in Pregnancy 
Quality of Life, PUQE- 24, 24- hour Pregnancy Unique Quantification of Emesis and nausea. A higher HIS or NVPQoL score indicates lower quality of 
life or higher impact on maternal well- being. A higher PUQE- 24 score indicates more severe symptoms.
Measures of HG severity at baseline as outcome: Model 1: univariable regression analysis; Model 2: multivariable regression analysis adjusted for age, 
prepregnancy BMI, ethnicity (western or not), and education level.
Measures of the clinical course of HG as outcome: Model 1: univariable regression analysis; Model 2: multivariable regression analysis adjusted for 
age, prepregnancy BMI, weight change at baseline, ethnicity (western or not), and education level.
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Previous studies did not find an association between TSH or FT4 
and readmission rates or the duration of inpatient hospital stay.29- 31 
Our study confirms these findings. Unlike the three currently avail-
able studies, our study is the first that performed a multivariable 
regression analysis and used TSH MoMs to correct for gestational 
fluctuations.
Another reason why clinicians may want to be informed about 
thyroid function in women with HG, is to rule out clinical hyper-
thyroidism as an alternative explanation for severe NVP symptoms, 
which may require thyreostatic therapy.32 One study in particular, 
which used PUQE- 24 scores to quantify NVP severity, focused on 
ruling out thyroid dysfunction among women with HG. They found 
no association between hyperthyroidism (3 out of 63 women) and 
the PUQE- 24 score and could therefore not support this alternative 
explanation for severe nausea and vomiting symptoms. In our study, 
we also found no association between TSH as well as FT4 and the 
PUQE- 24 score at baseline. Also no differences in PUQE- 24 score 
at baseline between women with and without GTT were found. 
Therefore, measuring thyroid function to rule out clinical hyper-
thyroidism as an explanation for severe nausea and vomiting seems 
unnecessary.
Our study is one of the few prospective cohort studies available 
including women admitted with HG using multiple measurements to 
assess HG severity and the clinical course of HG by using validated 
questionnaires. Furthermore, the women included in this study re-
flect a geographically representative sample of the Dutch popula-
tion, because data collection was from 19 different hospitals across 
the Netherlands. Another strength is that we used TSH MoM to 
allow us to adjust for pregnancy- related fluctuations of TSH related 
to the rise and fall of placental hCG as pregnancy progresses.
Our study has some limitations. First and foremost, TSH val-
ues were available for only two- thirds of the included women in our 
study, because TSH was not always included in local routine laboratory 
workup for HG. We also had to exclude women for TSH MoM and FT4 
analysis because of the lack of TSH medians or the lack of available fro-
zen stored blood samples. Together with loss to follow up, including a 
high rate of missing data, despite multiple efforts to retrieve these data, 
as described in the original MOTHER study, this may have limited our 
power to detect associations. Potentially, there may have been selective 
loss to follow up, with women with severe symptoms being too unwell 
to complete follow- up questionnaires. However, we found no evidence 
for selective participation: only the baseline characteristics gestational 
age and first admission of HG differed between the included and ex-
cluded women. Further baseline characteristics and measures of the 
severity and clinical course of HG did not differ, so it is unlikely to have 
altered our results. Second, in this study TSH and FT4 levels were not 
followed up, so we were unable to investigate whether thyroid suppres-
sion normalized without treatment later in pregnancy or after delivery. 
TA B L E  3  Multivariable linear and logistic regression to assess the association between FT4 and measures of the severity and clinical 
course of hyperemesis gravidarum
Model 1 Model 2
β 95% CI p β 95% CI p
HG severity at baseline
Weight change −0.13 −0.29 to 0.04 0.13 −0.14 −0.35 to 0.06 0.16
PUQE- 24 −0.05 −0.19 to 0.10 0.52 −0.05 −0.23 to 0.12 0.54
NVPQoL 0.65 −0.40 to 1.70 0.22 0.55 −0.63 to 1.74 0.35
HIS −0.02 −0.19 to 0.15 0.81 −0.06 −0.26 to 0.14 0.55
Clinical course of HG
PUQE- 24 1 week after inclusion −0.03 −0.21 to 0.15 0.72 0.01 −0.21 to 0.23 0.94
NVPQoL 1 week after inclusion ∫ −0.20 −2.37 to 2.12 0.87 0.80 −1.69 to 3.36 0.53
HIS 1 week after inclusion 0.15 −0.05 to 0.36 0.13 0.07 −0.15 to 0.29 0.50
Total days of hospital admission for HG ∫ 2.22 −0.50 to 5.02 0.10 3.05 −0.90 to 7.04 0.13
OR 95% CI p OR 95% CI p
Readmitted yes or no 1.03 0.95- 1.12 0.48 1.02 0.91- 1.14 0.72
Readmitted two or more times 1.02 0.92- 1.14 0.67 1.09 0.96- 1.23 0.19
A p value <0.05 was considered significant, represented with the therefore corresponding 95% % CI β is the unstandardized regression coefficient. 
OR is the odds ratio. ∫ is log transformed, back transformed and expressed in % of difference. Weight change is weight at baseline minus 
prepregnancy weight and can be <0 if women lost weight and can be >0 if women gain weight.
Abbreviations: BMI, body mass index; HG, hyperemesis gravidarum; HIS, Hyperemesis Impact Score; NVPQoL, Nausea and Vomiting in Pregnancy 
Quality of Life; PUQE- 23, 24- hour Pregnancy Unique Quantification of Emesis and nausea. A higher HIS or NVPQoL score indicates lower quality of 
life or higher impact on maternal wellbeing. A higher PUQE- 24 score indicates more severe symptoms.
Measures of HG severity at baseline as outcome: Model 1: univariable regression analysis; Model 2: multivariable regression analysis adjusted for 
gestational age, age, prepregnancy BMI, ethnicity (western or not) and education level.
Measures of clinical course of HG as outcome: Model 1: univariable regression analysis; Model 2: multivariable regression analysis adjusted for 
gestational age, age, prepregnancy BMI, weight change at baseline, ethnicity (western or not) and education level.
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TA B L E  4  Baseline characteristics and 
outcomes between women admitted 
for hyperemesis gravidarum included in 
this study with and without gestational 
thyrotoxicosis
GTT No GTT
pN = 21 N = 85
Demographics
Age (years) 29.67 ± 4.72 28.45 ± 4.90 0.31
Prepregnancy weight (kg) 69.40 ± 15.32 71.68 ± 15.41 0.55
Prepregnancy BMI (kg/m2) 25.12 ± 5.41 25.54 ± 5.17 0.75
Ethnic origin
Western 9 (42.9%) 50 (58.8%) 0.22
Non- western 8 (38.1%) 23 (27.1%)
Education level
Primary or secondary 5 (23.8%) 39 (45.9%) 0.13
Higher 9 (42.9%) 24 (28.2%)
Mental health disorder in medical 
historya 
2 (9.5%) 17 (20.0%) 0.35
HG in previous pregnancyb  9 (60%) 19 (34.5%) 0.08
HG in previous pregnancy requiring 
hospital admissionb 
4 (26.7%) 10 (18.2%) 1.00
Thyroid- stimulating hormone 0.33 ± 0.43 0.89 ± 0.67 0.00
Free thyroxine 26.37 ± 5.59 17.50 ± 2.26 0.00
Pregnancy characteristics
Primigravida 6 (28.6%) 30 (35.3%) 0.56
Twin pregnancy 1 (4.8%) 2 (2.4%) 0.49
Gestational age at onset of 
symptoms of HG (weeks)
6.00 (5.00- 6.50) 6.00 (5.00- 7.00) 0.60
Gestational age at baseline 8.00 (7.50- 9.50) 8.00 (7.00- 10.00) 0.89
First admission at study entry 18 (85.7%) 79 (92.9%) 0.38
Outcomes
HG severity at baseline
Weight change (kg) −3.87 ± 3.07 −2.96 ± 4.08 0.35
PUQE- 24 9.93 ± 3.77 10.36 ± 3.02 0.65
NVPQoL 176.21 ± 14.28 173.15 ± 23.58 0.64
HIS 26.80 ± 2.83 28.13 ± 3.96 0.23
Clinical course of HG
PUQE- 24 1 week after inclusion 9.00 (7.50- 10.00) 9.00 (6.00- 12.00) 1.00
NVPQoL 1 week after inclusion 73.50 (57.25- 84.75) 79.00 (58.75- 107.25) 0.47
HIS 1 week after inclusion 27.70 ± 1.64 24.98 ± 3.65 0.03
Duration of first admission (days) 4.00 (3.00- 5.00) 4.00 (3.00- 5.00) 0.37
Total days of hospital admission 
for HG
6.00 (4.00- 10.50) 5.00 (3.00- 7.50) 0.20
Readmitted 9 (42.9%) 32 (37.6%) 0.66
Readmitted two or more times 4 (19.0%) 11 (12.9%) 0.49
Data represented with mean ± standard deviation and median (interquartile range), unless stated 
otherwise; frequency (%). A p value <0.05 was considered significant.
Abbreviations: BMI, body mass index; GTT, gestational transient thyrotoxicosis: defined as women 
with a free thyroxine (FT4) level above 22.0 pmol/L; HG, hyperemesis gravidarum; PUQE- 24, 24- hour 
Pregnancy Unique Quantification of Emesis and nausea score. Weight change is weight at baseline 
minus prepregnancy weight and can be <0 if women lost weight and can be >0 if women gain weight; 
HIS, Hyperemesis Impact of Symptoms; NVPQoL, Nausea and Vomiting in Pregnancy Quality of Life. 
A higher PUQE- 24, HIS- or NVPQoL- score indicates more severe symptoms or lower quality of life.
aMental health disorder consists of an eating disorder, anxiety disorder. or a depressive disorder. 
bPercentage shown is frequency divided by number of multigravidas. 
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Previous literature suggested that TSH as well as FT4 levels return to 
normal by the second trimester in women with HG and GTT.33
5  |  CONCLUSION
Based on inconsistent findings from our study as well as from ear-
lier research, there seems little utility of thyroid measurement as a 
marker or predictor for the severity and clinical course of HG. The 
clinical relevance of measuring TSH in women with HG therefore 
seems low, making the likelihood that the thyroid plays an impor-
tant role in the etiology of HG also less likely. As advised in the HG 
guideline of the Nordic Federation of Societies of Obstetrics and 
Gynecology,34 thyroid function assessment should be reserved 
to rule out thyroid disease in women with clinical signs, such as 
goiter, or women with symptoms of clinical hyperthyroidism, such 
as marked tachycardia or prolonged atypical symptoms. Further re-
search in pursuit of a biomarker for diagnosis or as a predictor of 
disease course, or monitoring treatment effect in patients with HG 
is needed to optimize patient care and treatment.
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